Expert Interview
Digging into therapies in development for Congenital Adrenal Hyperplasia (CAH) including Neurocrine Biosciences gene therapy Crinecerfont
Ticker(s): NBIXInstitution: Oregon Health & Science University
- Associate Professor of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, School of Medicine
- Clinical interest is in Osteoporosis, Parathyroid Disease, Hypophosphatemia, Hypocalcemia, Hypothyroidism, Hyperthyroidism, Transgender Medicine, Male Hypogonadism, Adrenal Gland Disorders, Polycystic Ovarian Syndrome.
- Manages 15-20 patients with Osteogenesis Imperfecta and is familiar with the recent data for Setrusumab
Please describe your clinical practice; roughly how many patients with CAH do you currently manage?
Added By: ben_adminHow big you think the market is for Congenital Hyperplasia? How many patients do you think there are in the US, EU, by phenotype, and how many do you think would be interested in pursuing a treatment if it were available?
What is the unmet need, and what patients would stand to benefit from, from additional treatment?
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
